The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma†
Abstract
UNLABELLED: Although HCC is the third-leading cause of cancer-related deaths worldwide, there is only an elemental understanding of its molecular pathogenesis. In western countries, HCV infection is the main etiology underlying this cancer's accelerating incidence. To characterize the molecular events of the hepatocarcinogenic process, and to identify new biomarkers for early HCC, the gene expression profiles of 75 tissue samples were analyzed representing the stepwise carcinogenic process from preneoplastic lesions (cirrhosis and dysplasia) to HCC, including 4 neoplastic stages (very early HCC to metastatic tumors) from patients with HCV infection. We identified gene signatures that accurately reflect the pathological progression of disease at each stage. Eight genes distinguish between control and cirrhosis, 24 between cirrhosis and dysplasia, 93 between dysplasia and early HCC, and 9 between early and advanced HCC. Using quantitative real-time reverse-transcription PCR, we validated several novel molecular tissue markers for early HCC diagnosis, specifically induction of abnormal spindle-like, microcephaly-associated protein, hyaluronan-mediated motility receptor, primase 1, erythropoietin, and neuregulin 1. In addition, pathway analysis revealed dysregulation of the Notch and Toll-like receptor pathways in cirrhosis, followed by deregulation of several components of the Jak/STAT pathway in early carcinogenesis, then upregulation of genes involved in DNA replication and repair and cell cycle in late cancerous stages. CONCLUSION: These findings provide a comprehensive molecular portrait of genomic changes in progressive HCV-related HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Self-citationMinimum information about a microarray experiment (MIAME)-toward standards for microarray data
Brazma, A., Hingamp, P., Quackenbush, J., Sherlock, G., Spellman, P., Stoeckert, C., Aach, J., Ansorge, W., Ball, C. A., Causton, H. C., et al. (2001) · Nature Genetics · doi:10.1038/ng1201-365 · Cited by 4,109
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Self-citationLlovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Self-citationRising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Hepatocellular carcinoma pathogenesis: from genes to environment
Farazi, P. A., & DePinho, R. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1934 · Cited by 1,979
Molecular pathogenesis of human hepatocellular carcinoma
Thorgeirsson, S. S., & Grisham, J. W. (2002) · Nature Genetics · doi:10.1038/ng0802-339 · Cited by 1,439
Terminology of nodular hepatocellular lesions
Wanless, I. R. (1995) · Hepatology · doi:10.1002/hep.1840220341 · Cited by 1,130
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
Lee, J.-S., Heo, J., Libbrecht, L., Chu, I.-S., Kaposi-Novak, P., Calvisi, D. F., Mikaelyan, A., Roberts, L. R., Demetris, A. J., Sun, Z., et al. (2006) · Nature Medicine · doi:10.1038/nm1377 · Cited by 953
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling
Lee, J.-S., Chu, I.-S., Heo, J., Calvisi, D. F., Sun, Z., Roskams, T., Durnez, A., Demetris, A. J., & Thorgeirsson, S. S. (2004) · Hepatology · doi:10.1002/hep.20375 · Cited by 922
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
Capurro, M., Wanless, I. R., Sherman, M., Deboer, G., Shi, W., Miyoshi, E., & Filmus, J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00689-9 · Cited by 917
Ye, Q.-H., Qin, L.-X., Forgues, M., He, P., Kim, J. W., Peng, A. C., Simon, R., Li, Y., Robles, A. I., Chen, Y., et al. (2003) · Nature Medicine · doi:10.1038/nm843 · Cited by 850
Self-citationUbiquitous Activation of Ras and Jak/Stat Pathways in Human HCC
Calvisi, D. F., Ladu, S., Gorden, A., Farina, M., Conner, E. A., Lee, J., Factor, V. M., & Thorgeirsson, S. S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.006 · Cited by 710
Laurent–Puig, P., Legoix, P., Bluteau, O., Belghiti, J., Franco, D., Binot, F., Monges, G., Thomas, G., Bioulac–Sage, P., & Zucman–Rossi, J. (2001) · Gastroenterology · doi:10.1053/gast.2001.24798 · Cited by 582
Focus on hepatocellular carcinoma
Bruix, J., Boix, L., Sala, M., & Llovet, J. M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00058-3 · Cited by 570
Self-citationOkabe, H., Satoh, S., Kato, T., Kitahara, O., Yanagawa, R., Yamaoka, Y., Tsunoda, T., Furukawa, Y., & Nakamura, Y. (2001) · PubMed · Cited by 546
Iizuka, N., Oka, M., Yamada-Okabe, H., Nishida, M., Maeda, Y., Mori, N., Takao, T., Tamesa, T., Tangoku, A., Tabuchi, H., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12775-4 · Cited by 511
Llovet, J. M., Chen, Y., Wurmbach, E., Roayaie, S., Fiel, M. I., Schwartz, M., Thung, S. N., Khitrov, G., Zhang, W., Villanueva, A., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.014 · Cited by 386
Self-citationMultiple Tumor Suppressor Pathways Negatively Regulate Telomerase
Lin, S.-Y., & Elledge, S. J. (2003) · Cell · doi:10.1016/s0092-8674(03)00430-6 · Cited by 363
JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence
Santagata, S., Demichelis, F., Riva, A., Varambally, S., Hofer, M. D., Kutok, J. L., Kim, R., Tang, J., Montie, J. E., Chinnaiyan, A. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2500 · Cited by 338
Chuma, M., Sakamoto, M., Yamazaki, K., Ohta, T., Ohki, M., Asaka, M., & Hirohashi, S. (2003) · Hepatology · doi:10.1053/jhep.2003.50022 · Cited by 294
Hall, C. L., Yang, B., Yang, X., Zhang, S., Turley, M., Samuel, S., Lange, L. A., Wang, C., Curpen, G. D., Savani, R. C., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90048-9 · Cited by 293
Hepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets
Roberts, L. R., & Gores, G. J. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871200 · Cited by 289
Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis
Sicklick, J. K., Li, Y.-X., Jayaraman, A., Kannangai, R., Qi, Y., Vivekanandan, P., Ludlow, J. W., Owzar, K., Chen, W., Torbenson, M. S., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi292 · Cited by 270
Ge, X., Yamamoto, S., Tsutsumi, S., Midorikawa, Y., Ihara, S., Wang, S. M., & Aburatani, H. (2005) · Genomics · doi:10.1016/j.ygeno.2005.04.008 · Cited by 248
Iizuka, N., Oka, M., Yamada‐Okabe, H., Mori, N., Tamesa, T., Okada, T., Takemoto, N., Tangoku, A., Hamada, K., Nakayama, H., et al. (2002) · PubMed · Cited by 245
Kouprina, N., Pavlicek, A., Collins, N. K., Nakano, M., Noskov, V. N., Ohzeki, J.-I., Mochida, G. H., Risinger, J. I., Goldsmith, P., Gunsior, M., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi220 · Cited by 209
Farazi, P. A., Glickman, J. N., Jiang, S., Yu, A., Rudolph, K. L., & DePinho, R. A. (2003) · PubMed · Cited by 201
Seidler, D. G., Goldoni, S., Agnew, C., Cardi, C., Thakur, M. L., Owens, R. T., McQuillan, D. J., & Iozzo, R. V. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602853200 · Cited by 180
Newer markers for hepatocellular carcinoma
Marrero, J. A., & Lok, A. S. F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.024 · Cited by 175
Nam, S. W., Park, J. Y., Ramasamy, A., Shevade, S., Islam, A., Long, P. M., Park, C. K., Park, S. E., Kim, S. Y., Lee, S. H., et al. (2005) · Hepatology · doi:10.1002/hep.20878 · Cited by 167
Hepatitis C virus expression suppresses interferon signaling by degrading STAT1
Lin, W., Choe, W. H., Hiasa, Y., Kamegaya, Y., Blackard, J. T., Schmidt, E. V., & Chung, R. T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.02.006 · Cited by 160
Oncogenic role of the frizzled-7/β-catenin pathway in hepatocellular carcinoma
Merle, P., Kim, M., Herrmann, M., Gupte, A., Lefrançois, L., Califano, S., Tre´po, C., Tanaka, S., Vitvitski, L., Monte, S. D. L., et al. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.05.018 · Cited by 158
Bièche, I., Asselah, T., Laurendeau, I., Vidaud, D., Degot, C., Paradis, V., Bédossa, P., Valla, D. C., Marcellin, P., & Vidaud, M. (2004) · Virology · doi:10.1016/j.virol.2004.11.009 · Cited by 152
Fong, C. W., Chua, M., McKie, A. B., Ling, S. H. M., Mason, V., Li, R., Yusoff, P., Lo, T. L., Leung, H. Y., So, S. K., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1072 · Cited by 150
Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma.
Smith, M. W., Yue, Z. N., Geiss, G. K., Sadovnikova, N. Y., Carter, V. S., Boix, L., Lázaro, C. A., Rosenberg, G. B., Bumgarner, R. E., Fausto, N., et al. (2003) · PubMed · Cited by 148
Self-citationWirths, O., Waha, A., Weggen, S., Schirmacher, P., Kühne, T., Goodyer, C. G., Albrecht, S., von Schweinitz, D., & Pietsch, T. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000059926.66359.bd · Cited by 141
Patil, M. A., Chua, M., Pan, K., Lin, R., Lih, C., Cheung, S., Ho, C., Li, R., Fan, S.-T., Cohen, S. N., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208479 · Cited by 137
Molecular-based prediction of early recurrence in hepatocellular carcinoma
Kurokawa, Y., Matoba, R., Takemasa, I., Nagano, H., Dono, K., Nakamori, S., Umeshita, K., Sakon, M., Ueno, N., Oba, S., et al. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.04.031 · Cited by 119
Delpuech, O., Trabut, J., Carnot, F., Feuillard, J., Bréchot, C., & Kremsdorf, D. (2002) · Oncogene · doi:10.1038/sj.onc.1205392 · Cited by 95
Kienitz, A., Vogel, C., Morales, I., Müller, R., & Bastians, H. (2005) · Oncogene · doi:10.1038/sj.onc.1208589 · Cited by 92
Molecular Profiling of Hepatocellular Carcinomas (HCC) Using a Large-Scale Real-Time RT-PCR Approach
Paradis, V., Bièche, I., Dargère, D., et al. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63700-5 · Cited by 89
Wurmbach, E., Yuen, T., & Sealfon, S. C. (2003) · Methods · doi:10.1016/s1046-2023(03)00161-0 · Cited by 78
Self-citationMolecular prognostication of liver cancer: End of the beginning
Thorgeirsson, S. S., Lee, J., & Grisham, J. W. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.01.008 · Cited by 73
Antifibrotic Agents for Liver Disease
Albanis, E., & Friedman, S. L. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01143.x · Cited by 68
Self-citationAmplifications of DNA primase 1 (PRIM1) in human osteosarcoma
Yotov, W. V., Hamel, H., Rivard, G.-E., Champagne, M. A., Russo, P., Leclerc, J., Bernstein, M. L., & Levy, E. H. (1999) · Genes Chromosomes and Cancer · Cited by 52
Expression profiling of cyclin B1 and D1 in cervical carcinoma.
Zhao, M., Kim, Y. T., Yoon, B., Kim, S. W., Kang, M., Kim, S., Kim, J., Kim, J. W., & PARK, Y. (2006) · PubMed · Cited by 42
Gramantieri, L., Chieco, P., Giovannini, C., Lacchini, M., Treré, D., Grazi, G. L., Venturi, A., & Bolondi, L. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.07.017 · Cited by 38
Yang, C., Su, J.-Y., Tsou, A., Chau, G., Liu, H., Chen, C., Chien, C.-Y., & Chou, C. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.005 · Cited by 31
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“The performance of this signature was externally validated in a different set of samples [118,119].”
BackgroundLlovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Self-citationMYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Forner, A., Vilana, R., Ayuso, C., Bianchi, L., Solé, M., Ayuso, J. R., Boix, L., Sala, M., Varela, M., Llovet, J. M., et al. (2008) · Hepatology · doi:10.1002/hep.21966 · Cited by 1,032
Self-citation
Metadata
- Authors
- Wurmbach, E., Chen, Y., Khitrov, G., Zhang, W., Roayaie, S., Schwartz, M., Fiel, I., Thung, S., Mazzaferro, V., Bruix, J., Bottinger, E., Friedman, S., Waxman, S., & Llovet, J. M.
- Venue
- Hepatology
- Published
- 2007-04
- Volume
- 45
- Issue
- 4
- Pages
- 938-947
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2039394834
- Cited by
- 722
- References
- 51
- FWCI
- 17.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.